AR043168A1 - Compuestos heterociclicos derivados de oxadiazol, oxazol e isoxazol - Google Patents

Compuestos heterociclicos derivados de oxadiazol, oxazol e isoxazol

Info

Publication number
AR043168A1
AR043168A1 ARP040100440A ARP040100440A AR043168A1 AR 043168 A1 AR043168 A1 AR 043168A1 AR P040100440 A ARP040100440 A AR P040100440A AR P040100440 A ARP040100440 A AR P040100440A AR 043168 A1 AR043168 A1 AR 043168A1
Authority
AR
Argentina
Prior art keywords
alkoxy
hydroxy
alkyl
isoxazol
oxazol
Prior art date
Application number
ARP040100440A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR043168A1 publication Critical patent/AR043168A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a compuestos de la fórmula (1), en donde: R1 es hidroxi, alcoxi C1-4, amino, alquilamino C1-4, dialquilamino C1-4, benciloxi o alcanoilo C2-7; R2 es alquilo C1-4, alcoxi C1-4; alcoxi(C1-4)-alcoxi(C1-4) CF3, halógeno, alquilamino C1-4, dialquilamino C1-4, dialquilamino(C1-4)-alcoxi(C1-4) o N-alcoxi(C1-4)-alquilo(C1-4)-N-alquilamino(C1-4), N-alquilapiperazinilo C1-4, morfolinilo, pirrolidinilalcoxi C1-4, en donde los radicales alquilo C1-4, en R2 además están opcionalmente sustituidos por alquilo C1-4, halógeno, ciano, amino, alcoxi o alquiltio; X es N u O; Y es N, O o CH; Z es N o CH; y W es N o CH; siempre que a) R1 no sea hidroxi o alcoxi C1-4 cuando R2 sea CF3, X sea O, Y sea CH, Z sea N y W sea CH, b) R1 no sea hidroxi o alcoxi C1-4 cuando R2 es CF3 o cloro, X es N, Y es O, Z es CH y W es CH, c) R1 no sea hidroxi cuando R2 sea CF3, X sea O, Y sea N, Z sea CH y W sea CH y d) X e Y simultáneamente no sean O, sus sales; su preparación, su uso y composiciones farmacéuticas que lo contienen, útiles para el tratamiento de la enfermedad de Parkinson.
ARP040100440A 2003-02-14 2004-02-12 Compuestos heterociclicos derivados de oxadiazol, oxazol e isoxazol AR043168A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303503.7A GB0303503D0 (en) 2003-02-14 2003-02-14 Organic compounds

Publications (1)

Publication Number Publication Date
AR043168A1 true AR043168A1 (es) 2005-07-20

Family

ID=9953078

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100440A AR043168A1 (es) 2003-02-14 2004-02-12 Compuestos heterociclicos derivados de oxadiazol, oxazol e isoxazol

Country Status (14)

Country Link
US (1) US7432293B2 (es)
EP (1) EP1597243A1 (es)
JP (1) JP2006517564A (es)
CN (2) CN101665469A (es)
AR (1) AR043168A1 (es)
AU (1) AU2004212151B2 (es)
BR (1) BRPI0407479A (es)
CA (1) CA2515847A1 (es)
GB (1) GB0303503D0 (es)
MX (1) MXPA05008584A (es)
PE (1) PE20050193A1 (es)
PL (1) PL376754A1 (es)
TW (1) TW200502225A (es)
WO (1) WO2004072050A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1618098B1 (en) 2003-04-11 2014-11-19 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US9051342B2 (en) * 2004-10-13 2015-06-09 Ptc Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases
NZ562197A (en) 2005-04-08 2010-09-30 Ptc Therapeutics Inc Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
MX2007013263A (es) 2005-04-26 2008-01-22 Neurosearch As Novedosos derivados oxadiazol y su uso medico.
CA2647903C (en) 2006-03-30 2016-12-13 Ptc Therapeutics, Inc. Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
FR2903108B1 (fr) * 2006-07-03 2008-08-29 Sanofi Aventis Sa Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique.
FR2903105A1 (fr) 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
FR2903107B1 (fr) 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
WO2008030570A1 (en) 2006-09-08 2008-03-13 Ptc Therapeutics, Inc. Processes for the preparation of 1,2,4-oxadiazole benzoic acids
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
MX344418B (es) 2006-09-25 2016-12-15 Ptc Therapeutics Inc Formas cristalinas del acido 3-[5- 2- fluorofenil)- [1,2,4] oxadiazol-3-il]- benzoico.
EP2068871B1 (en) 2006-09-25 2013-12-25 PTC Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
JP2010506840A (ja) * 2006-10-12 2010-03-04 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス突然変異抑制治療用の経口的に活性な１，２，４−オキサジアゾールの投与方法
US8222243B2 (en) 2007-08-27 2012-07-17 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
BRPI0913609B8 (pt) 2008-06-09 2021-05-25 Univ Muenchen Ludwig Maximilians composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas e em depósitos de imagem de proteína agregada, uso do mesmo, e kit
KR101273765B1 (ko) * 2008-06-24 2013-06-12 아이알엠 엘엘씨 Ｇ 단백질-커플링된 수용체를 조정하는 화합물 및 방법
FR2933609B1 (fr) 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
WO2011009484A1 (en) * 2009-07-22 2011-01-27 Novartis Ag Arylpyrazoles and arylisoxazoles and their use as pkd modulators
FR2950053B1 (fr) 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR2955110A1 (fr) * 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
CN103249726B (zh) * 2010-10-14 2015-01-07 第一三共株式会社 酰基苯衍生物
AU2014345595B2 (en) * 2013-11-05 2019-01-24 Bayer Animal Health Gmbh Novel compounds for combating arthropods
CN112979575A (zh) 2014-03-06 2021-06-18 Ptc医疗公司 1,2,4-噁二唑苯甲酸的药物组合物和盐
WO2017075312A1 (en) 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methods for treating epilepsy
JP7283699B2 (ja) 2017-05-12 2023-05-30 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04295470A (ja) 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−ｂ酵素阻害活性を有する１，２，４−オキサジアゾール誘導体及びその製造法
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
IT1300055B1 (it) 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
AU4394799A (en) * 1998-07-01 2000-01-24 Takeda Chemical Industries Ltd. Retinoid-associated receptor regulators
JP2000080086A (ja) * 1998-07-01 2000-03-21 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
PT1070708E (pt) * 1999-07-21 2004-05-31 Hoffmann La Roche Derivados de triazol
CZ2002599A3 (cs) * 1999-08-19 2002-06-12 Nps Pharmaceuticals Inc. Heteropolycyklické sloučeniny a jejich pouľití jako antagonistů metabotropního receptoru glutamátu
ES2292830T3 (es) * 2001-02-21 2008-03-16 Astrazeneca Ab Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
EP1405636A4 (en) * 2001-06-26 2009-04-15 Takeda Pharmaceutical REGULATOR OF RECTINTOR FUNCTION RELATING TO RETINOIDS

Also Published As

Publication number Publication date
TW200502225A (en) 2005-01-16
CN101665469A (zh) 2010-03-10
PE20050193A1 (es) 2005-04-11
PL376754A1 (pl) 2006-01-09
MXPA05008584A (es) 2005-11-04
EP1597243A1 (en) 2005-11-23
US7432293B2 (en) 2008-10-07
GB0303503D0 (en) 2003-03-19
CA2515847A1 (en) 2004-08-26
CN100475795C (zh) 2009-04-08
AU2004212151A1 (en) 2004-08-26
AU2004212151B2 (en) 2008-09-04
WO2004072050A1 (en) 2004-08-26
JP2006517564A (ja) 2006-07-27
CN1747942A (zh) 2006-03-15
US20060089365A1 (en) 2006-04-27
BRPI0407479A (pt) 2006-02-07

Similar Documents

Publication Publication Date Title
AR043168A1 (es) Compuestos heterociclicos derivados de oxadiazol, oxazol e isoxazol
CR10145A (es) Derivados de tropano útiles en terapia (divisional exp. 6800)
CY1110951T1 (el) Αζαϊνδολες
AR038045A1 (es) Agentes terapeuticos
NO20055590L (no) Kinaseinhiberende fosfonatanaloger
AR054214A1 (es) Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c.
UY28369A1 (es) Agentes terapéuticos
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
CO5700776A2 (es) Compuestos utiles para el tratamiento de enfermedades
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
MX9404749A (es) Heterociclos de fenilo como inhibidores de cox-2.
UY24239A1 (es) Composiciones insecticidas acaricidas y nematicidas que contienen una amina biciclica, procedimiento para preparacion de dichas aminas y metodo para combatir y controlar dichas pestes en un locus
AR023659A1 (es) Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
CY1111759T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη συγκεκριμενων τριαζολοπυριμιδινων ως ρ2τ ανταγωνιστων
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
AR057461A1 (es) Derivados de pirazol, proceso de preparacion, composiciones farmaceuticas y usos
AR055295A1 (es) Compuestos inhibidores del transportador de glicina
ID23954A (id) Tetrahidrogama-karbolin
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
BRPI0407386A (pt) Derivados de álcool de amino, composições farmacêuticas contendo os mesmos e uso destes
ES2089041T5 (es) Compuestos de piridinasulfonamida sustituida, composiciones herbicidas que los contienen, y procedimiento para su preparacion.
CL2004000521A1 (es) MEZCLA HERBICIDA QUE COMPRENDE N-(5,7-DIMETOXI(1,2,4)TRIAZOLO [1,5-a]PIRIMIDIN-2IL)-2-METOXI-4-(TRIFLUORO METIL)1-3-PIRIDINSULFONAMIDA (PIROXSULAM), OTRO HERBICIDA Y OPCIONALMENTE UN ANTIDOTO; COMPOSICION HERBICIDA; PROCESO DE PREPARACION DE LA COMPO
SV1999000075A (es) Derivados de 3-(2-oxo-[1,3']bipirrolidinil-3-ilidenemetil)-cefemos
AR041029A1 (es) Compuestos quimicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure